Cheng Li | Drug Delivery Systems | Best Researcher Award

Prof. Cheng Li | Drug Delivery Systems | Best Researcher Award

Profess at Shanghai Fourth People’s Hospital | School of Medicine | Tongji Universit | China

Prof. Cheng Li  is a distinguished chief physician, professor, and doctoral supervisor in anesthesiology. A visiting scholar at Harvard University , he directs a National Key Clinical Specialty and serves as a leading researcher at the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation . Prof. Li has pioneered 11 innovative technologies enhancing elderly critical care and brain protection . His prolific academic, clinical, and mentorship contributions have earned him national recognition . Dedicated to advancing anesthesia and perioperative science, Prof. Li is shaping the future of surgical medicine through groundbreaking innovation and academic excellence.

Profile 

Scopus

Education

Prof. Cheng Li completed his medical education from top-tier Chinese medical institutions . His rigorous academic training in anesthesiology and perioperative medicine laid the foundation for his specialization in critical care for elderly patients and neurological function regulation . He further enhanced his expertise as a visiting scholar at Harvard University , gaining international exposure and experience. As a committed academician, he continues to mentor postgraduate and doctoral students . Prof. Li’s comprehensive education, both domestic and abroad, has equipped him with deep clinical insight, strong research methodology skills, and a global perspective on patient care .

Experience 

Prof. Li Cheng has over two decades of clinical and research experience in anesthesiology and perioperative medicine . He serves as the Director of a National Key Clinical Specialty and leads a research team at the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation . He is actively involved in hospital technology adoption and has led the development of 11 technologies for elderly and critically ill patients . Prof. Li holds more than 20 academic positions and has supervised 24 postdoctoral, Ph.D., and master’s students . He continues to impact both policy and practice in Chinese medical institutions .

Awards 

Prof. Cheng Li has received numerous prestigious awards recognizing his academic and clinical excellence. These include Shanghai Outstanding Academic Leader, Shanghai Young Top Talent, and the Third Prize of the Shanghai Silver Snake Award. He was named “China’s Good Doctor”, the First Shanghai Good Doctor, and received the Outstanding Young Medical Talent – “Medical Star of Shanghai”. In 2022, he was honored as the “Outstanding Teacher of the Most Beautiful Professional Ethics” by Tongji University. His team has earned collective honors such as the Advanced Collective of the National Health and Wellness System.

Research Focus 

Prof. Li’s research is centered on anesthesia and perioperative management in elderly and critically ill patients. His work on brain protection and neurological regulation has led to 11 innovative clinical technologies. He is actively exploring biomarker-based monitoring, neuro-anesthetic pharmacology, and personalized anesthesia protocols in surgical settings. His involvement in intraoperative brain function control, post-operative cognitive disorder prevention, and advanced anesthesia devices underscores his commitment to translational medicine. Prof. Li’s research integrates clinical expertise with cutting-edge science to elevate surgical safety and efficiency, especially for high-risk elderly patients.

Publication Top Notes

Title: Three-stage sequential targeted nasal drops for correcting abnormal mitochondrial division in microglia
Journal: Bioactive Materials
Year: 2025

Title: Lactate inhibits T-cell activation in sepsis through CD40LG downregulation and SOCS3-mediated JAK1/STAT3 pathway suppression
Journal: Biochimica et Biophysica Acta – Molecular Basis of Disease
Year: 2025

Title: Clinical biomarkers of perioperative neurocognitive disorder: initiation and recommendation
Journal: [Journal name not specified]
Year: 2025
Cited by: 1

Title: Thermo-responsive and biodegradable MoS2-based nanoplatform for tumor therapy and postoperative wound management
Journal: Journal of Colloid and Interface Science
Year: 2025
Cited by: 2

Title: Disrupting the activity of endogenous gas neurotransmitters: a therapeutic strategy using engineered metal–organic frameworks for cancer
Journal: Medical Gas Research
Year: 2025

Conclusion

In conclusion, Prof. Cheng Li’s impactful innovations, prolific research output, and exceptional leadership in anesthesiology make him a highly deserving candidate for the Best Researcher Award. His clinical and academic contributions have significantly advanced patient care and scientific knowledge in anesthesiology, earning national recognition and academic prestige. With ongoing focus and minor enhancements in international outreach and interdisciplinary integration, he stands poised to further shape the global landscape of perioperative and critical care research.

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Dr. Alexis LeVee at UCLA, United States.

Dr. A. LeVee is a physician-scientist specializing in medical oncology with a focus on breast cancer and translational immunotherapy. Currently a Clinical Instructor at UCLA and a Hematology/Oncology Fellow at City of Hope, Dr. LeVee combines clinical expertise with cutting-edge research in tumor immunology, the microbiome, and novel therapeutic biomarkers. A graduate of Duke University and Tufts Medical School, they are a recipient of multiple national awards, including the ASCO Conquer Cancer Young Investigator Award. With over 10 peer-reviewed publications and leadership in high-impact studies, Dr. LeVee is shaping the future of personalized cancer care and precision immunotherapy.

Publication Profile 

Google Scholar

Education

Dr. LeVee earned a B.A. in Chemistry with minors in Economics and Biology from Duke University (2013) 🧪, followed by an M.D. from Tufts University School of Medicine (2019) 🩺. They completed an Internal Medicine residency at Cedars-Sinai Medical Center (2019–2022) and are currently completing a Hematology/Medical Oncology Fellowship at City of Hope Comprehensive Cancer Center (2022–2025) 🧠. Their diverse training spans top-tier academic institutions and reflects a deep foundation in both clinical medicine and biomedical sciences, equipping them with the tools to integrate research and practice in complex oncology care.

Experience

Dr. LeVee currently serves as Clinical Instructor at UCLA (2025–Present) and Chief Fellow at City of Hope (2023–Present) in the Hematology/Medical Oncology Fellowship Program. Previously, they worked as a Business Analyst at Orange Advisory Group (2013–2015), combining data-driven insight with clinical research. Dr. LeVee has held numerous leadership and committee roles at Cedars-Sinai and City of Hope, contributing to medical education and institutional quality improvement. Their multidisciplinary background and academic leadership experience reflect a strong trajectory toward becoming a leader in translational oncology and academic medicine.

Awards 

Dr. LeVee has earned multiple prestigious awards, including the Young Investigator Award from ASCO, Conquer Cancer Foundation, and MOASC 🏆. Additional accolades include the Coltman Scholar Award and Early Investigator Award from the San Antonio Breast Cancer Symposium (2024), the ASCO Merit Award (2024), and finalist status for the Rubenstein Award for Resident Research (2022). Earlier honors include fellowships from Tufts, American Thoracic Society, and DukeEngage. These awards reflect their innovative research and impact in oncology, particularly in microbiome science, breast cancer immunotherapy, and biomarker discovery.

Research Focus 

Dr. LeVee’s research bridges clinical oncology and translational science, focusing on breast cancer, tumor microenvironment, and immunotherapy 🧬. Their work investigates how microbiota, immune signatures, and biomarkers predict treatment response in triple-negative and HER2+ breast cancers. With funding from ASCO, Biocodex, and City of Hope, Dr. LeVee leads multiple studies analyzing metagenomic and metatranscriptomic profiles of fecal microbiota in patients receiving chemoimmunotherapy. They also explore the cardiotoxic effects of cancer therapies and immuno-radiation synergy. Their goal is to develop precision tools that enhance treatment personalization and patient outcomes in cancer care.

Publication Top Notes